Brian Meshkin

TL;DR: In this paper, a composition and custom business model and methods to measure genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplements with custom formulations to optimize health outcomes.

TL;DR: It is proposed that a novel approach to nutritional supplementation may be required to target the RDS role in obesity, and Genotrim, a DNA based customized nutraceutical has been designed and is currently under investigation in several clinical studies.

TL;DR: GenoTrim™, a DNA-customized nutritional solution, has been developed and is currently under investigation in several clinical studies, and it is proposed that a novel approach to nutritional supplementation may be required to target the role of RDS in obesity.

TL;DR: It is hypothesized that the combination of enkephalinase inhibition, neurotransmitter precursor loading, brain tryptophan enhancing and COMT inhibition as well as DNA analysis of the individual's genome, may be useful as an adjunct to therapy when used in outpatient recovery, specifically to assist in reducing craving behavior and preventing relapse.

TL;DR: The evidence suggests that ADHD is primarily a polygenic disorder involving at least 50 genes, including those encoding enzymes of neurotransmitter metabolism, neurotransmitter transporters and receptors, which is likely to establish ADHD firmly as a biological disorder and to lead to better methods of diagnosis and treatment.